Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
IMNN Imunon Inc
- Stocks
- Healthcare
- NASDAQ: IMNN
Price (delayed)
$0.74
Market cap
$10.82M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.36
Enterprise value
$8.96M
Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of
Highlights
IMNN's debt is down by 33% YoY and by 12% from the previous quarter
The company's EPS rose by 33% YoY and by 16% QoQ
The equity has dropped by 95% year-on-year and by 89% since the previous quarter
Imunon's quick ratio has plunged by 75% YoY and by 59% from the previous quarter
Key stats
What are the main financial stats of IMNN
Market
Valuations
Earnings
Shares outstanding
14.62M
Market cap
$10.82M
Enterprise value
$8.96M
Price to earnings (P/E)
N/A
Price to book (P/B)
23.94
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$18.27M
Net income
-$17.79M
EBIT
-$17.79M
EBITDA
-$17.06M
Free cash flow
-$16.11M
Per share
Balance sheet
Liquidity
EPS
-$1.36
EPS diluted
-$1.36
Free cash flow per share
-$1.11
Book value per share
$0.03
Revenue per share
$0
TBVPS
$0.47
Total assets
$6.86M
Total liabilities
$6.41M
Debt
$1.01M
Equity
$452,028
Working capital
-$704,931
Debt to equity
2.23
Current ratio
0.88
Quick ratio
0.5
Net debt/EBITDA
0.11
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-175%
Return on equity
-428%
Return on invested capital
N/A
Return on capital employed
-1,670.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IMNN stock price
How has the Imunon stock price performed over time
Intraday
-7.34%
1 week
-27.45%
1 month
-67.4%
1 year
-34.51%
YTD
-22.11%
QTD
-29.52%
Financial performance
How have Imunon's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$18.27M
Net income
-$17.79M
Gross margin
N/A
Net margin
N/A
IMNN's operating income is up by 10% YoY and by 4.5% QoQ
The net income has grown by 6% YoY and by 4.4% from the previous quarter
Price vs fundamentals
How does IMNN's price correlate with its fundamentals
Growth
What is Imunon's growth rate over time
Valuation
What is Imunon stock price valuation
P/E
N/A
P/B
23.94
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 33% YoY and by 16% QoQ
IMNN's price to book (P/B) is 128% higher than its last 4 quarters average of 10.5
The equity has dropped by 95% year-on-year and by 89% since the previous quarter
Efficiency
How efficient is Imunon business performance
Imunon's return on assets has shrunk by 108% YoY and by 13% QoQ
The ROE has contracted by 42% from the previous quarter
Dividends
What is IMNN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IMNN.
Financial health
How did Imunon financials performed over time
The total assets is 7% more than the total liabilities
Imunon's quick ratio has plunged by 75% YoY and by 59% from the previous quarter
The current ratio has plunged by 65% YoY and by 47% from the previous quarter
IMNN's debt is 123% more than its equity
The equity has dropped by 95% year-on-year and by 89% since the previous quarter
IMNN's debt is down by 33% YoY and by 12% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.